Sygnature Discovery has appointed Dr Andy Black as non-executive chairman. Andy brings over 20 years of experience in life sciences to Sygnature Discovery, including 13 years at CEO and Board level. He has a proven track record in entrepreneurship, devising, and leading strategic change, and possesses functional expertise in numerous areas, including pharmaceutical research, clinical development, drug regulation, pharmacovigilance and quality, and compliance. Andy joins Sygnature from Kinapse, where he was a co-founder and the CEO. Andy is also Head of Strategic Industry Partnerships at King’s College London where he is responsible for developing large-scale translational research partnerships between leading life sciences companies and King’s Health Partners.
